Effect of Daily Steps on Fat Metabolism

Metabolic Syndrome Clinical Trial

Official title:

Effect of Daily Ambulatory Activity on the Responses to Acute Aerobic Exercise.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03697382
• Other study ID #: 2018-08-0031
• Status: Completed
• Phase: N/A
• Start date: September 29, 2018
• Est. completion date: May 31, 2020

Study information

• Verified date: September 2021
• Source: University of Texas at Austin
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Reduced ambulatory activity has been shown to effect the response to a high fat tolerance test (HFTT) after acute exercise. This study will evaluate the effect of varying levels of daily ambulation on response to a HFTT after an acute aerobic exercise bout.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: May 31, 2020
• Est. primary completion date: February 15, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 40 Years

Eligibility

Exclusion Criteria:

• Cardiovascular problems (e.g. pre-existing heart issues, coronary artery disease, hypertension, etc.)
• Respiratory problems
• Musculoskeletal problems that prevent prolonged sitting or exercise
• Obesity
• Susceptibility to fainting
• Pregnancy

Related Conditions & MeSH terms

• Atherosclerosis
• Metabolic Syndrome

Intervention

Behavioral:
• Very Low Steps
Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trials. Following this 2-day period, they will undergo the Very Low Stepping trial with the acute bout of exercise on day 2. Day 3 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
• Low Steps
Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trials. Following this 2-day period, they will undergo the Low Stepping trial with the acute bout of exercise on day 2. Day 3 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
• Moderate Steps
Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trials. Following this 2-day period, they will undergo the Moderate Stepping trial with the acute bout of exercise on day 2. Day 3 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.

Locations

Country	Name	City	State
United States	University of Texas at Austin Human Performance Laboratory	Austin	Texas

Sponsors (1)

Lead Sponsor	Collaborator
University of Texas at Austin

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	6-Hour Plasma Triglyceride Area Under the Curve	Areas under the curve for triglyceride concentration will be calculated for hourly samples from a 6-hour lipid tolerance test.	6-hours
Secondary	6-Hour Plasma Insulin Area Under the Curve	Areas under the curve for insulin concentration will be calculated for hourly samples from a 6-hour lipid tolerance test	6-hours
Secondary	6-Hour Plasma Glucose Area Under the Curve	Areas under the curve for glucose concentration will be calculated for hourly samples from a 6-hour lipid tolerance test.	6-hours